RENASCENT III: First in Human Evaluation of the Novel Thin Strut MAGNITUDE Sirolimus-Eluting Ultra-High Molecular Weight MAGNITUDE Bioresorbable Scaffold: 9-Month Imaging and 2-Year Clinical Results

Circ Cardiovasc Interv. 2021 May;14(5):e010013. doi: 10.1161/CIRCINTERVENTIONS.120.010013. Epub 2021 May 18.
No abstract available

Keywords: angina, unstable; coronary artery disease; myocardial ischemia; polymer; stent.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorbable Implants
  • Cardiovascular Agents* / adverse effects
  • Coronary Artery Disease* / drug therapy
  • Coronary Artery Disease* / therapy
  • Drug-Eluting Stents*
  • Everolimus
  • Humans
  • Molecular Weight
  • Percutaneous Coronary Intervention*
  • Prosthesis Design
  • Sirolimus / adverse effects
  • Treatment Outcome

Substances

  • Cardiovascular Agents
  • Everolimus
  • Sirolimus